Coleford Investment Management Ltd. reduced its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 91,052 shares of the medical instruments supplier's stock after selling 1,441 shares during the period. Becton, Dickinson and Company makes up 5.9% of Coleford Investment Management Ltd.'s portfolio, making the stock its 8th largest holding. Coleford Investment Management Ltd.'s holdings in Becton, Dickinson and Company were worth $20,856,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Becton, Dickinson and Company by 50.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after purchasing an additional 27,581 shares during the last quarter. Foster Victor Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the first quarter worth $6,406,000. GAMMA Investing LLC lifted its position in shares of Becton, Dickinson and Company by 29.9% during the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock worth $744,000 after purchasing an additional 748 shares during the last quarter. Finally, Ritholtz Wealth Management bought a new stake in Becton, Dickinson and Company during the 1st quarter valued at about $224,000. 86.97% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the stock. Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Wall Street Zen lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a report on Friday, May 2nd. Finally, Citigroup downgraded Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their price objective for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $219.22.
Get Our Latest Report on BDX
Becton, Dickinson and Company Stock Down 0.8%
Shares of Becton, Dickinson and Company stock traded down $1.37 on Monday, reaching $177.48. The stock had a trading volume of 656,972 shares, compared to its average volume of 2,145,177. The company has a 50 day moving average price of $173.51 and a 200 day moving average price of $204.06. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The stock has a market capitalization of $50.87 billion, a P/E ratio of 33.90, a P/E/G ratio of 1.35 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the previous year, the firm earned $3.17 EPS. The company's quarterly revenue was up 4.5% compared to the same quarter last year. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.34%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's payout ratio is currently 79.39%.
Insider Activity at Becton, Dickinson and Company
In related news, EVP David Shan sold 1,166 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.36% of the stock is owned by insiders.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
